迈科康生物筹备A股上市：董事长陈德祥是海归博士，曾任职于辉瑞、诺华

Core Viewpoint - Chengdu Maikang Biological Technology Co., Ltd. (hereinafter referred to as Maikang Bio) has completed its IPO counseling filing with the Sichuan Securities Regulatory Bureau, aiming for A-share listing, with China International Capital Corporation as the counseling institution [1]. Group 1: Company Overview - Maikang Bio was established on April 29, 2016, with a registered capital of 37.261289 million yuan [1]. - The company is primarily engaged in the research, development, production, and commercialization of innovative vaccines and novel adjuvants, recognized as a national high-tech enterprise and a "little giant" enterprise in Sichuan Province [1][2]. - The controlling shareholder is Chengdu Qianding Enterprise Management Consulting Co., Ltd., which directly holds 22.09% of the company's shares [3]. Group 2: Product Development - Maikang Bio has diversified its product development pipeline targeting infectious diseases, allergic diseases, and oncology, including several preventive vaccines for major infectious diseases and therapeutic vaccines for HPV infections, allergic diseases, and cancer, with three projects currently in clinical trial stages [2]. - To advance the industrialization of novel adjuvants and human vaccines, the company has nearly completed the construction of an innovative vaccine production platform and has initiated the establishment of an industrialization base [2]. Group 3: Leadership and Expertise - The chairman and general manager of Maikang Bio is Chen Dexiang, who holds a Ph.D. in immunology from Mississippi State University and has over 30 years of experience in vaccine and adjuvant development at Pfizer, Novartis, and PATH [4][7]. - Chen has led numerous major international public health projects funded by international organizations, foundations, and national governments, with over 20 vaccine development projects resulting in multiple products launched globally [4][7]. - He has published more than 60 academic papers related to vaccines in top-tier journals such as Science and Nature Medicine [4][7].